Connection

Raymund Razonable to Antibodies, Monoclonal, Humanized

Back to Details
This is a "connection" page, showing publications Raymund Razonable has written about Antibodies, Monoclonal, Humanized.
Raymund Razonable
Connection Strength
0.498
Antibodies, Monoclonal, Humanized
  1. Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019. J Infect Dis. 2021 10 28; 224(8):1278-1286.
    View in: PubMed
    Score: 0.197
  2. Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19. J Clin Invest. 2021 10 01; 131(19).
    View in: PubMed
    Score: 0.196
  3. A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID-19 in skilled care facilities. J Am Geriatr Soc. 2021 04; 69(4):868-873.
    View in: PubMed
    Score: 0.047
  4. GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study. Mayo Clin Proc. 2020 11; 95(11):2382-2394.
    View in: PubMed
    Score: 0.045
  5. Diffuse C4d staining of peritubular capillaries in renal allograft following bamlanivimab therapy. Am J Transplant. 2022 01; 22(1):289-293.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.